Heath Lukatch

Heath Lukatch is a Partner in Novo Ventures, Novo A/S.

Heath Lukatch joined Novo A/S in 2006 working out of the San Francisco, California office. He is chairman of the board of directors of Inogen, Inc. and NeuroTherapeutics Pharma, Inc., and a member of the board of directors of Amira Pharmaceuticals, Inc. AnaptysBio, Inc. and Synosia Therapeutics.

Prior to joining Novo A/S, Heath was a Managing Director for Piper Jaffray Ventures and SightLine Partners, and a bench scientist at Cetus, Chiron and Roche Bioscience. While at Piper Jaffray and Sightline he was responsible for biotech venture investments and served on the boards of several biotech and medical device companies. Previously, he was at McKinsey & Co. where his primary focus was on strategy consulting for biopharmaceutical companies.

Heath also brings entrepreneurial experience from his role as founder and CEO of AutoMate Scientific, Inc. a biotechnology instrumentation company.

Heath holds a PhD in neuroscience from Stanford University and a BA in biochemistry from the University of California at Berkley.